Dynorphin (2-17), Amide, Porcine Mechanisms, Clinical Applic

Dynorphin (2-17), Amide, Porcine: Mechanisms, Clinical Applications, and Research Perspectives

Introduction
Dynorphin (2-17), amide, porcine, is a synthetic peptide fragment derived from the endogenous opioid peptide dynorphin A, specifically encompassing amino acids 2 through 17 of the parent molecule. Dynorphins are a class of opioid peptides that play a crucial role in modulating nociception, stress responses, and neuroendocrine functions through their interaction with opioid receptors, particularly the kappa-opioid receptor (KOR) (Chavkin et al., 1982, Science). The (2-17) fragment retains significant biological activity and is often utilized in research to dissect the structure-activity relationships and receptor selectivity of dynorphin peptides.

Mechanistically, Dynorphin (2-17), amide, acts primarily as an agonist at the KOR, though it may also interact with other opioid receptor subtypes at higher concentrations (Simonin et al., 1998, J Pharmacol Exp Ther). The amide modification at the C-terminus enhances peptide stability and bioavailability, making it a valuable tool for in vitro and in vivo studies. The porcine sequence is highly homologous to human dynorphin, supporting its translational relevance in preclinical models.

[Related: Decanoyl-RVKR-CMK] Clinical Value and Applications
Dynorphin (2-17), amide, porcine, has emerged as a critical research tool in the investigation of pain modulation, neurodegenerative diseases, and psychiatric disorders. Its primary clinical value lies in its ability to selectively activate KORs, enabling the study of kappa-opioid signaling pathways distinct from those mediated by mu- and delta-opioid receptors. This selectivity is particularly important given the unique physiological and behavioral effects associated with KOR activation, including analgesia, dysphoria, and modulation of stress responses (Bruchas et al., 2010, Pharmacol Rev).

In pain research, Dynorphin (2-17) is used to model endogenous pain control mechanisms and to evaluate the efficacy of novel KOR-targeted analgesics. It has also been employed in studies of spinal cord injury, where dynorphin peptides are implicated in secondary injury processes and neuropathic pain (Vanderah et al., 1996, J Neurosci). Beyond pain, KOR agonists like Dynorphin (2-17) are being explored for their potential in treating mood disorders, substance abuse, and neuroinflammation.

[Related: Protein kinase inhibitor, potent and cell permeable] Key Challenges and Pain Points Addressed
Current opioid-based analgesics, such as morphine and fentanyl, primarily target the mu-opioid receptor, leading to significant side effects including respiratory depression, tolerance, dependence, and risk of abuse (Volkow et al., 2014, N Engl J Med). In contrast, KOR agonists like Dynorphin (2-17) offer a non-addictive alternative for pain management, with a lower propensity for respiratory depression and abuse liability (Wee & Koob, 2010, Pharmacol Ther).

However, KOR activation is associated with dysphoric and psychotomimetic effects, which have limited the clinical development of KOR agonists as analgesics. Dynorphin (2-17), as a research tool, enables the dissection of these effects at the molecular and circuit levels, facilitating the development of biased agonists or modulators that retain analgesic efficacy while minimizing adverse effects (Schattauer et al., 2017, Neuropsychopharmacology).

[Related: geneticin selection] Additionally, dynorphin peptides have been implicated in the pathogenesis of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), where they may contribute to excitotoxicity and neuronal injury. Dynorphin (2-17) provides a means to model these processes in vitro and in vivo, supporting the identification of novel neuroprotective strategies (Faden et al., 1989, Science).

Literature Review
1. **Chavkin, C., James, I. F., & Goldstein, A. (1982). Science.**
This seminal study identified dynorphin as an endogenous ligand for the kappa-opioid receptor, demonstrating its potent analgesic effects and receptor selectivity. The work laid the foundation for subsequent research into dynorphin fragments and their physiological roles.

2. **Vanderah, T. W., et al. (1996). J Neurosci.**
This investigation explored the role of dynorphin peptides in spinal cord injury, showing that elevated dynorphin levels contribute to neuropathic pain and secondary neuronal damage. The study utilized dynorphin fragments, including (2-17), to delineate receptor-mediated and non-receptor-mediated effects.

3. **Bruchas, M. R., Land, B. B., & Chavkin, C. (2010). Pharmacol Rev.**
This comprehensive review summarized the physiological and behavioral effects of KOR activation, highlighting the therapeutic potential and challenges associated with KOR-targeted drugs. The role of dynorphin peptides in stress, addiction, and mood regulation was emphasized.

4. **Simonin, F., et al. (1998). J Pharmacol Exp Ther.**
This study characterized the pharmacological profiles of various dynorphin fragments, including (2-17), across different opioid receptor subtypes. The findings supported the use of Dynorphin (2-17) as a selective KOR agonist in experimental models.

5. **Schattauer, S. S., et al. (2017). Neuropsychopharmacology.**
The authors investigated the signaling pathways downstream of KOR activation, identifying biased agonism as a strategy to separate therapeutic effects from adverse outcomes. Dynorphin (2-17) was used to probe receptor signaling in neuronal cultures.

6. **Faden, A. I., et al. (1989). Science.**
This research demonstrated that dynorphin peptides can induce neurotoxicity independent of opioid receptor activation, implicating them in excitotoxic injury following CNS trauma. The study provided a rationale for targeting dynorphin-mediated pathways in neuroprotection.

7. **Wee, S., & Koob, G. F. (2010). Pharmacol Ther.**
This review discussed the role of KOR and dynorphin in addiction and stress-related disorders, highlighting the potential for KOR agonists and antagonists in treating substance use disorders.

Experimental Data and Results
Experimental studies utilizing Dynorphin (2-17), amide, porcine, have provided critical insights into its pharmacological properties and biological effects. In vitro assays have confirmed its high affinity and selectivity for the KOR, with nanomolar potency in receptor binding and functional assays (Simonin et al., 1998, J Pharmacol Exp Ther). Electrophysiological studies in rodent brain slices have demonstrated that Dynorphin (2-17) inhibits neurotransmitter release in key pain and reward circuits, consistent with KOR-mediated presynaptic inhibition (Bruchas et al., 2010, Pharmacol Rev).

In vivo, intrathecal administration of Dynorphin (2-17) in animal models produces robust antinociceptive effects, which are reversed by selective KOR antagonists, confirming receptor specificity (Vanderah et al., 1996, J Neurosci). However, at higher doses or with repeated administration, Dynorphin (2-17) can induce motor deficits and neurotoxicity, reflecting its dual role in modulating pain and contributing to secondary injury in the CNS (Faden et al., 1989, Science).

Behavioral studies have shown that Dynorphin (2-17) administration can produce dysphoric and aversive effects in rodents, paralleling the clinical observations of KOR agonists in humans (Schattauer et al., 2017, Neuropsychopharmacology). These findings underscore the importance of dose optimization and receptor selectivity in the development of KOR-targeted therapeutics.

Usage Guidelines and Best Practices
Dynorphin (2-17), amide, porcine, is supplied as a lyophilized powder and should be reconstituted in sterile water or physiological buffer prior to use. For in vitro studies, typical working concentrations range from 10 nM to 10 μM, depending on the assay and cell type. In vivo, intrathecal or intracerebroventricular administration is commonly employed, with doses adjusted based on animal species, weight, and experimental endpoints (Vanderah et al., 1996, J Neurosci).

It is essential to include appropriate controls, such as vehicle-treated and KOR antagonist-treated groups, to confirm receptor-mediated effects. Due to the potential for neurotoxicity at high concentrations, dose-response studies should be conducted to identify the minimum effective dose. Researchers should also consider the amide modification, which may alter peptide stability and pharmacokinetics compared to unmodified peptides.
< Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 31 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11569199